Table 1.

NRF2 expression and correlation with ovarian cancer subtypes.

Tissues Studied	Proteins Analysed	Results	Ref.
10 normal tissues	NQO1 NRF2	NQO1 and NRF2 increased expression in ovarian carcinoma compared with normal and pre-cancerous lesions. NRF2 expression increases with ovarian carcinoma stage advancing	[25]
20 benign tumours:
12 serous
8 mucinous
20 borderline tumours:
12 serous
8 mucinous
50 ovarian carcinomas:
35 serous
15 mucinous
108 ovarian carcinomas: 47 Serous 23 Mucinous 13 Endometrioid 25 Clear cells	KEAP1 E-cadherin NRF2	Serous carcinoma has a higher KEAP1 cytoplasmic, NRF2 nuclear expression and lower E-cadherin membrane positivity than mucinous, endometrioid and clear cell carcinomas. Patients with serous carcinoma are older in age and show highest KEAP1 expression and least percentage of E-cadherin immunoreactivity.	[26]
100 Clear cell carcinomas: 81 Chemosensitives 19 Chemoresistants	KEAP1 NRF2	Low KEAP1 expression is associated with disease recurrence and death. High KEAP1 expression is predictive of better overall and disease-free survival. No association among chemoresistance, NRF2 and KEAP1 expression is detected but patients with high KEAP1 expression have significantly lower recurrence rates and death. Significant and positive correlations between the intensities of cytoplasmic NRF2 and KEAP1 expression.	[27]
156 EOC: 110 serous 21 endometrioid 12 clear cells 13 mucinoses	ERα NRF2	Nuclear NRF2 expression is low in serous, clear cell, and endometrioid carcinomas but high in the mucinous subtype. Low nuclear NRF2 expression is associated with age of patients. No association of ERα expression among subtypes but high ERα expression is present in low-graded carcinomas compared to high-graded ones. NRF2 cytoplasmic expression correlates with ERα expression. Both NRF2 cytoplasmic and ERα expressions are associated with longer overall survival in serous carcinoma.	[28]
156 EOC: 110 serous 21 endometrioid 12 clear cells 13 mucinoses	PRA PRB NRF2	NRF2 cytoplasmic expression is correlated with both PRA and PRB expressions, and is associated with a significant impact on overall survival. Grading, FIGO, lymph node involvement (pN), and distant metastasis (pM) show no significant differences.	[29]

EOC: Epithelial ovarian cancer; PRA: Progesterone Receptor A; PRB: Progesterone Receptor B; ERα: Estrogen Receptor α.